Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Forgent Power Solutions Inc. Class A Common Stock (FPS) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance

Forgent Power Solutions Inc. Class A Common StockTrade
Kymera Therapeutics Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Forgent Power Solutions Inc. Class A Common Stock vs Kymera Therapeutics Inc. Common Stock — how do they compare? Forgent Power Solutions Inc. Class A Common Stock trades at $31.76 (market cap $9.93B), while Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B). The key difference: Forgent Power Solutions Inc. Class A Common Stock and Kymera Therapeutics Inc. Common Stock are close in size by market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Forgent Power Solutions Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Forgent Power Solutions Inc. Class A Common Stock for 0 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.

FPSKYMR
Market Cap
$9.93B$8.87B
Volume
7,516,726779,107
Sector
IndustrialsHealth
52-Week High
$64.59$127.31
52-Week Low
$27.97$55.80
Typical Hold Time
0 Days0 Days
Enterprise Value
$10.54B$8.26B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Forgent Power Solutions Inc. Class A Common Stock

Forgent Power Solutions (FPS) trades at $36.17, down 2.48% on the day, following a strong earnings-driven rally. The stock shows neutral technical signals with support at $35 and resistance at $37. Recent Q2 2026 earnings beat expectations with EPS of $0.25 versus $0.24 expected, continuing a pattern of quarterly outperformance. The company reported record $3 billion backlog and strong data center demand driving growth.

FPS presents significant upside potential with analyst consensus target of $55.20 (52.9% upside) and 85.7% buy ratings. However, high valuation multiples (P/E 120.57, P/S 6.21) and negative 2025 net income of -$6.17M create valuation concerns. Key risks include execution on $3B backlog and potential overvaluation amid AI infrastructure hype.

Kymera Therapeutics Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FPS
100% Buy0% Sell
Avg holding period · 0 Days
KYMR
100% Buy0% Sell
Avg holding period · 0 Days

About Forgent Power Solutions Inc. Class A Common Stock

Forgent Power Solutions designs and manufactures electrical distribution equipment, including transformers, switchgear, transfer switches, and prefabricated power systems, for data centers, the power grid, and industrial facilities, manufacturing across multiple product categories in-house through a network of manufacturing campuses in US.

Read more on FPS →

About Kymera Therapeutics Inc. Common Stock

Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.

Read more on KYMR →